BridgeBio Pharma (BBIO) Cost of Revenue (2021 - 2026)

BridgeBio Pharma has disclosed Cost of Revenue across 6 years of filings, most recently posting $9.9 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $9.9 million, up 276.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.3 million (up 377.48% YoY), and the FY2025 annual result was $21.0 million, up 440.54% from the prior year.
• Cost of Revenue came in at $9.9 million for Q1 2026 at BridgeBio Pharma, up from $8.1 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $9.9 million in Q1 2026 to a low of $598000.0 in Q3 2023.
• The 5-year median for Cost of Revenue is $675500.0 (2022), against an average of $2.5 million.
• Across the five-year window, Cost of Revenue tumbled 58.28% in 2022 and jumped 997.49% in 2025, its largest moves.
• BridgeBio Pharma's Cost of Revenue stood at $647000.0 in 2022, then decreased by 7.57% to $598000.0 in 2023, then jumped by 248.49% to $2.1 million in 2024, then surged by 289.01% to $8.1 million in 2025, then gained by 22.6% to $9.9 million in 2026.
• The last three Cost of Revenue figures came in at $9.9 million (Q1 2026), $8.1 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.